These findings will help in differentiating between the pro- and the anti-tumor drivers on the cancer cells and within the TME and present opportunities for drug interventions aimed at blocking ephrinB2 signaling for maximal therapeutic benefit. Here, EFNB2 is linked to neoplasm.